Our study represented the first comprehensive evaluation of the association between levels of IgG and IgA antibody targeting major EBV glycoproteins involved in viral entry, including gp350, gH/gL, gB, and gp42, and neutralizing ability against EBV infection of epithelial cells and B cells and the risk of NPC. This evidence concerns the gene CD79A and Epstein-Barr virus infection.